An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Insmed
- 03 Mar 2023 Status changed from not yet recruiting to recruiting.
- 20 Feb 2023 Planned initiation date changed from 28 Feb 2023 to 12 Apr 2023.
- 20 Feb 2023 Planned initiation date changed from 31 Jan 2023 to 28 Feb 2023.